Biosimilars promise cost savings and improved patient access in Latin America, yet face significant regulatory and ...

Real-world data confirm Mvasi's safety as a cost-effective alternative to reference bevacizumab (Avastin) for treating ...

Government price negotiations under the Inflation Reduction Act may hinder biosimilar development, impacting drug costs and ...

Number 5: Sarfaraz K. Niazi, PhD, argues that the FDA can accelerate biosimilar entry by changing guidance under the Biologics Price Competition and Innovation Act (BPCIA) without needing ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

Biosimilars face a potential void as biologics lose exclusivity, prompting urgent calls for policy reform and enhanced ...

Number 5: Long-term data from the SAME study confirm that switching to infliximab biosimilars is safe and effective for patients with inflammatory bowel disease (IBD). Number 4: Significant knowledge ...